Impact of the New Regulation of Clinical Trials: A First View of Research Ethics Committees from Catalonia (Spain)

Clinical research is essential for advancing medical knowledge and patient care, but it must be conducted within a rigorous ethical framework. In Spain, a dynamic regulatory environment culminated in the application of Regulation (EU) No. 536/2014 via Royal Decree 1090/2015, which brought sweeping changes to the ethical review process for clinical trials^[1][2][3]. Catalonia—the region with the highest number of RECs in Spain—serves as an informative model to assess the initial impact of this regulation^[4][5].

·        Regulation (EU) No. 536/2014: Streamlines procedures, harmonizes assessments across Europe, emphasizes participant safety, and mandates greater transparency in trial reporting.

·        Royal Decree 1090/2015: Spanish implementation, introduces a single National Ethics Committee opinion (replacing review by each participating site's committee), strengthens REC credentials, and requires the inclusion of at least one patient or layperson per REC^[1][2][3][6].

·        Key Innovations:

o   Single REC opinion valid nationwide

o   Coordinated review between REC and the Spanish Agency of Medicines and Medical Devices (AEMPS)

o   Standardized composition and accreditation of RECs^[3][6]

A mixed-methods analysis was conducted drawing on surveys and annual activity reports from 31 accredited Catalan RECs before and after the regulatory shift. Quantitative activity metrics (committee meetings, number of trials evaluated) and member satisfaction scores were assessed. Data were analyzed using descriptive statistics, non-parametric tests, and qualitative review of open-ended responses^[4][5].

Activity Metrics: A Quantitative Perspective

Key findings:

·        The number of REC meetings held annually remained stable.

·        A sharp decline in the number of clinical trial evaluations was observed in the period following regulatory implementation, despite minor fluctuations in previous years^[4][5].

Table: Impact on REC Activity and Member Satisfaction

Graph: Annual Number of Clinical Trials Evaluated by Catalan RECs

(The above reflects available quantitative observations on the Catalan REC system^[4][5].)

Member and Committee Satisfaction

·        Satisfaction before regulation (median): 8/10

·        Satisfaction after regulation (median): 6/10

·        Major determinants of dissatisfaction:

o   Increased administrative burden for local RECs

o   Marginalization of site-specific ethical concerns

o   Perceived loss of influence over trial approval for local investigators

Despite reductions in evaluative variability and faster national approvals, a majority of REC members report a less favorable experience under the new system^[4][1].

Positive Impacts

·        Harmonization and Consistency: The new regulation reduced variability in REC evaluation outcomes, ensuring that multicenter trials receive more uniform ethical scrutiny^[1][2].

·        Administrative Efficiency: Centralized reviews via a single accredited REC expedited the overall approval process^[1][3].

·        Increased Transparency: Mandated registration and reporting requirements enhance public trust in clinical research^[3][6].

Challenges and Concerns

·        Reduced REC Involvement: Local RECs report feeling sidelined in trial oversight, raising concerns about insufficient consideration of local context and hospital-specific factors^[4][5].

·        Satisfaction Decline: The new procedure, while administratively streamlined, has reduced member satisfaction—potentially due to decreased active participation and perceived fragmentation of ethical oversight^[4][5].

·        Learning Curve and Remodelling: Significant remodelling of committee functions required new standard operating procedures, retraining, and workflow realignment, imposing a transitional burden on personnel^[4][5].

Qualitative Perspectives

·        While the benefits of standardization and speed are recognized, doubts and negative elements (e.g., administrative overload, lack of responsiveness to local needs) currently predominate among committee members in Catalonia^[4][5].

Spain’s pioneering early adoption of the new European regulation on clinical trials—viewed through the lens of Catalan Research Ethics Committees—offers instructive lessons for harmonizing ethical oversight while maintaining local accountability. Early data from Catalonia reveal administrative efficiencies but at a cost of reduced REC activity and lower satisfaction among committee members. Continuous evaluation and potential adjustment are warranted to balance centralized efficiency with the expertise and contextual sensitivity local RECs provide^[4][5][1].

Table 1. REC Activity and Satisfaction Pre- and Post-Regulation

Recommendations

·        Mechanisms for local REC input should be retained or strengthened to ensure contextual relevance without sacrificing the benefits of centralization.

·        Ongoing training and adaptation support for REC members are crucial to facilitate the transition.

·        Further research is needed to assess patient perspectives, long-term trends, and possible adjustments to the regulatory framework.

1.      Quintana Riera, Salvador, et al. "Impact of the new regulation of clinical trials: A first view of research ethics committees from Catalonia (Spain)." Dialnet, 2024.

2.      "Impact of the New European Regulation on Clinical Trials in the Research Ethics Committees from Catalonia." Latin American Journal of Pharmacy, vol. 40, no. 1, 2021, pp. 1–7.

3.      "Spain passes new regulations on clinical trials to increase transparency and simplify procedures." Biocat, 2016.

4.      "New regulation on clinical trials in Spain." Leon Research, 2023.

5.      "Royal Decree 1090/2015, of 4 December, regulating clinical trials with medicinal products, Ethics Committees for Investigation with medicinal products and the Spanish Clinical Studies Registry." AEMPS, 2024.

6.      "New clinical trials regulation in Spain: analysis of royal decree 1090/2015." PMC, 2016.